More importantly, using a variety of mouse models, including immunocompetent mice, Rag2 KO mice (lacking T- and B cells) and immunodeficient NSG mice (lacking NK-, T-, and B cells), we demonstrated that EHMT2 loss promoted NK cell-mediated tumor suppression, regardless of the presence or absence of T- and B cells. Here, EHMT2 is linked to neoplasm.